Oral presentation highlights safety profile of MRX34, microRNA target engagement, and multiple clinical responses in cancer patients
In an oral presentation (Abstract # 2508 "MRX34, a Liposomal miR-34
Mimic, in Patients with Advanced Solid Tumors: Final Dose-Escalation
Results from a First-in-Human Phase 1 Trial of microRNA Therapy"),
"The potential of microRNA therapeutics to simultaneously repress
multiple oncogenic and immune-evasion pathways represents an exciting
new approach to treating cancer," commented
Data highlights include:
Vincent O'Neill, M.D., Mirna's Chief Medical Officer commented, "We're pleased to report our clinical progress to date with the first microRNA candidate for cancer. MRX34 is a promising, first-in-class therapeutic candidate with potential as a single agent and in combination with targeted and immune therapies. With the safety profile and recommended dose established, we look forward to advancing the development of MRX34 into Phase 2 later in 2016."
The presentation may be accessed from the Events & Presentations section of the Company's website.
About Mirna Therapeutics, Inc.
Mirna is a clinical stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics and is the first to establish clinical proof-of-concept for a microRNA replacement therapy for cancer. Mirna's lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is currently being studied in a Phase 1 clinical trial in patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress the immune checkpoint signaling molecule PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs potent anti-cancer agents and less susceptible to drug resistance. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapeutic modalities, such as targeted therapies and immuno-oncology agents. The Company was founded in 2007 and is located in Austin, Texas.
For more information, visit www.mirnarx.com.
To the extent that statements contained in this press release are not
descriptions of historical facts regarding Mirna, they are
forward-looking statements reflecting the current beliefs and
expectations of management made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995, including
statements regarding our plans for MRX34 development; our preclinical
and clinical activity and results of our clinical development program;
and the potential efficacy of MRX34, including as a combination therapy.
Such forward-looking statements involve substantial risks and
uncertainties that could cause our clinical development program, future
results, performance or achievements to differ significantly from those
expressed or implied by the forward-looking statements. Such risks and
uncertainties include, among others, the uncertainties inherent in the
clinical drug development process, including the outcomes of clinical
trials, the regulatory approval process, our substantial dependence on
MRX34, our commercialization plans and efforts and other matters that
could affect the availability or commercial potential of our product
candidates. Mirna undertakes no obligation to update or revise any
forward-looking statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks relating
to our business in general, see our Annual Report on Form 10-K filed
News Provided by Acquire Media